A jury decided Johnson & Johnson must pay a Philadelphia man $2.5 million in damages “for failing to warn that its Risperdal antipsychotic could cause gynecomastia, which is abnormal development of breasts in males,” reported WSJ Pharmalot.
“The lawsuit was brought by the family of an autistic boy who took the drug in 2002 and later developed size 46 DD breasts,” stated Pharmalot. “At the time, Risperdal was not approved for children. J&J hid data from the FDA, prescribing doctors, and parents. Documents showed they knew there was much higher percentage of children getting gynecomastia than they admitted.”
The case, with many others pending, was previously reported in Mad in America.
Johnson & Johnson Loses Trial Over Risperdal And Male Breasts (WSJ Pharmalot, February 24, 2015)